Semaglutide vs. Tirzepatide
A practical comparison of two weekly medicines, including how they work, what studies can tell us, and how a clinician helps choose between them.
Semaglutide and tirzepatide can both support meaningful weight management when prescribed for the right person and paired with ongoing care. They are not identical, and the best choice is not simply the medicine with the largest average number in a headline. Your health history, goals, tolerability, access, and the exact FDA-approved product all matter.
The difference, in plain English
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Both can reduce appetite, increase fullness, and affect digestion. Their different receptor activity is one reason their average outcomes and side-effect patterns are studied separately.
Product names and indications matter. Wegovy is an FDA-approved semaglutide product for chronic weight management in eligible people and for certain cardiovascular risk reduction. Zepbound is an FDA-approved tirzepatide product for chronic weight management in eligible people and for moderate-to-severe obstructive sleep apnea in adults with obesity. Ozempic and Mounjaro are approved for type 2 diabetes, not simply interchangeable weight-loss labels.
What head-to-head studies show
In a 72-week randomized trial of adults with obesity without diabetes, tirzepatide produced greater average percentage weight reduction than semaglutide at the doses studied. Gastrointestinal symptoms were the most common adverse events in both groups and were generally most noticeable during dose escalation.
That result describes averages in a defined trial. It does not guarantee that one medicine will be better for a specific person. Previous response, medical history, side effects, coverage, supply, dosing preferences, and the ability to stay in follow-up can change the practical choice.
What you may notice
Many people first notice earlier fullness, smaller portions feeling satisfying, or less persistent food noise. Changes in weight and health markers tend to unfold over months, not days. Early weeks are often about learning how your appetite and digestion respond while the dose increases gradually.
Nausea, diarrhea, vomiting, constipation, abdominal discomfort, and indigestion are among the common effects listed in product labeling. Some people have few symptoms; others need slower adjustments, nutrition support, or a different plan. Never accelerate the schedule or change the dose without your prescriber.
Who might discuss either option with a clinician
Adults who meet the labeled eligibility criteria for chronic weight management may discuss these medicines with a clinician. The decision should consider BMI and weight-related conditions as well as medical history, current medicines, prior treatment, and personal priorities.
Tell your clinician about pregnancy or pregnancy plans, a personal or family history of medullary thyroid carcinoma or MEN 2, pancreatic or gallbladder problems, kidney concerns, severe gastrointestinal symptoms, diabetes medicines, and any planned surgery or sedation. Each label contains specific warnings and instructions.
Practical support that matters with either medicine
A steady routine can make treatment easier to live with: eat slowly, notice fullness, choose smaller meals when needed, drink regularly, and build meals around protein, produce, and other foods you tolerate. Resistance training and adequate nutrition help support strength and body composition during weight loss.
Follow-up should cover more than the scale. Energy, strength, blood pressure, glucose measures when relevant, sleep, digestion, and quality of life can all help a clinician decide whether the plan is working.
A calm safety and product check
Both medicines have important contraindications, warnings, and possible adverse reactions. Seek urgent care for severe or persistent symptoms as directed by your clinician and product labeling. A prescriber should provide clear instructions for missed doses, side effects, procedures involving anesthesia, and when to pause or stop.
Compounded semaglutide or tirzepatide is not an FDA-approved generic and is not reviewed by FDA for safety, effectiveness, or quality before marketing. FDA has recently increased scrutiny of misleading compounded GLP-1 promotion. If compounding is proposed for a patient-specific medical need, ask why, which pharmacy will fill the prescription, what ingredient and concentration are used, and how dosing will be verified.
Frequently asked questions
Which causes more weight loss: semaglutide or tirzepatide?
Tirzepatide produced greater average weight reduction in a recent head-to-head trial at the doses studied. That does not predict an individual result or replace a clinical decision.
Can I switch directly from one to the other?
Switching requires a prescriber-led plan. Dose timing, tolerability, health history, and the exact products matter; do not convert doses on your own.
Are compounded versions generic Wegovy or Zepbound?
No. Compounded drugs are not FDA-approved generics and have not undergone FDA premarket review for safety, effectiveness, or quality.
How quickly should the dose increase?
Follow the schedule for the exact prescribed product unless your clinician changes it. Escalation is designed to support tolerability and should not be rushed.
Medical sources
- 01Wegovy Prescribing InformationU.S. Food and Drug Administration · 2026
- 02Zepbound Prescribing InformationU.S. Food and Drug Administration · 2026
- 03Tirzepatide as Compared with Semaglutide for the Treatment of ObesityThe New England Journal of Medicine · 2025
- 04FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food and Drug Administration · 2026
Treatment requires clinician evaluation. Education does not establish eligibility or guarantee a prescription.